Osiris Therapeutics, Inc. (NASDAQ:OSIR)

Burning cash like a rocket burning fuel at takeoff, Osiris is developing unique and much needed products. It may be several years before this stock takes off in the direction of ISRG but if they are successful in product development the potential is here. I believe adult stem cell research and development is the only ethical stem cell path and have put my money where my heart is!

From the depths of the abyss comes Osiris Therapeutics which boasts a loathful balance sheet. Their mid-phase trials have been less than bullish suggesting little to moderate success of their inflammatory drug used after knee surgery. They are trading at 30 times sales and get those tissues ready because you'll be crying from laughing so hard, 2131 times book value!!! Revenues are increasing far too slowly to drive a profit at these levels and the company is quickly running out of cash. With 22M left in the bank and a burn rate of practically 3.5M a month i'll leave you to do the math! So in 6 months when they are practically out of cash and relying on a 30M committment from their CEO and begging for a cash infusion remember these warnings....

Nero

Sagetrade

Stem cell trials are running now involving recreating heart muscle and knee cartilage and have a good degree of being successful. If so, this would be an incredible medical breakthrough.

Interesting technology supported by worthy research...upcoming phase III trial results will reveal more...merits a few speculative dollars at this point.

I can't believe that this stock has a 1 star CAPS rating. Yes this stock has taken a beating, but watch out - this company will be one of the leaders (it already is, but it will be even more) in the stem cell arena within the next few years. So much potential and no one seems to take notice - YET. Now is the time to accumulate shares and you will reap the benefits in the long term - isn't that what investing is all about?

I love insider purchasing into stock price weakness.

Remains an extremely risky/speculative play, STEMMING from its potential thus far.

osir was one of the first "stem cell" or "regenerative medicine" companies. This is a HUGE GROWTH AREA for the foreseeable future (1-5 and 5-10 yr). All big pharma and biotech are eyeing this space. When people said embryonic cells are the way, osir stuck to what it knew and moved science and products forward. They have a GREAT intellectual property position due to their early commitment to this space. Their patents on the adult derived MSCs is good to 2013 for autlogous use (self), to 2019 for allogeneic use (think one donor providing stem cells for 100 people)and their recent phase 1 clinical reuslts in the cardiac field has a patent that runs to 2018. So, whether they get to these therapeutic products by their own growth or through partners or by being a acquisition target, osir is a rock solid player compared to ALL other companies in this space. They are moving several products thru clinical trials so bigger company's are watching their progress and they know about osir's patent position. One of them is going to take the plunge and stock price will double. Any of their products will suddenly push them to the 1B capitalization. I, for one will hold for 2-3 yrs when max benefit will be clear.

This is "adult" stem cells we are talking about. The Russians are a decade ahead of us on this, and they have truly shown cures that almost beggar the word "miracle" Stemedica is a prominent Russian co that will soon open clinics in "neutral" countries like ,Bahamas Bermuda,Caymans etc, where rich people can get "regenerated" remember Yeltsin, loking like death warmed over, dissappeared for a couple of months a few years ago. He went to a Stemedica clinc, where his liver and kidneys were restored in VERY SIMPLE PROCEDURES! When he returned, looking 20 yrs younger, amazement ruled.

ride back up

Adult stem cell company. Positive Phase 1 trial results. Indications of both safety and efficacy in repairing heart damage from heart attacks.Also positive indications for cardio-pulminary condotions. Stock appears to have bottomed and price has spiked upward.

Lots of play towards the upside. A positive story must be on it's way.

Osiris Therapeutics, Inc. is a stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. The sole product the company markets i.e. Osteocel happens to be the only stem cell-containing product in the market. The company has three product candidates in clinical trials.

The financial performance of the company for the fiscal 2007 was dismal. Its net losses widened from $20 million to $45 million. However it’s not its financials but the outlooks on its product pipeline that holds the key to its fortunes. This fact was amply displayed in February when the stock fell more than 10% on a single day on back of adverse news on Chondrogen stem cell.

The company, leveraging its proprietary technology is the market leader in stem cell therapy. Prochymal(Phase III) for steroid-refractory Graft versus Host Disease (GvHD) has the potential to be the first FDA-approved stem cell biologic for GvHD.

The company’s valuation still seems to be rich considering the fact that it’s likely to lose cash at operating level for some time to come. The stock does offer some hope for those who want to take leap of faith. However at the end of the day it’s a loss making company in a niche where regulatory environment is still not very clear. The market’s risk appetite is shrinking by the minute and hence stable cash generating/dividend paying companies would be in vogue. Hence the stock may under perform in the medium term.

Leader of the pack in an industry that is about to get alot of press.

This Co. has the ONLY commercially available product containing stem cells in the U.S.

Multiple pending clinical trials with short-term endpoints